Bellicum Pharmaceuticals Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. | Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| |
Founding Date | Founding Date 2004 | Founding Date 2002 | Founding Date 2006 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Houston, US HQ Houston, US Houston, US South San Francisco, US | Locations San Diego, US HQ San Diego, US | |
Employees | Employees 1386% increase | Employees 1,32324% increase | Employees 31019% decrease |
Valuation ($) | Valuation ($) 778.3 k | Valuation ($) 34.6 b | Valuation ($) 2 m |
Financial | |||
Revenue (est.) | Revenue (est.) $1.5m (FY, 2022) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) |
Net income | Net income ($25m) (FY, 2022) | Net income ($440.2m) (FY, 2023) | Net income ($577.8m) (FY, 2022) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 42.6m |